Omega Non Current Assets Total from 2010 to 2024
| OMGA Stock | USD 0.80 0.06 6.98% |
Non Current Assets Total | First Reported 2010-12-31 | Previous Quarter 114.5 M | Current Value 120.2 M | Quarterly Volatility 39.8 M |
Check Omega Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Omega Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Depreciation And Amortization of 7.1 M or Interest Expense of 189.8 K, as well as many indicators such as Price To Sales Ratio of 49.92, Dividend Yield of 0.0 or PTB Ratio of 2.94. Omega financial statements analysis is a perfect complement when working with Omega Therapeutics Valuation or Volatility modules.
Omega | Non Current Assets Total |
Latest Omega Therapeutics' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Omega Therapeutics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Omega Therapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Omega Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Omega Non Current Assets Total Regression Statistics
| Arithmetic Mean | 19,919,673 | |
| Geometric Mean | 6,390,998 | |
| Coefficient Of Variation | 199.96 | |
| Mean Deviation | 26,166,544 | |
| Median | 3,466,000 | |
| Standard Deviation | 39,831,280 | |
| Sample Variance | 1586.5T | |
| Range | 116.7M | |
| R-Value | 0.63 | |
| Mean Square Error | 1025.6T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | 5,631,117 | |
| Total Sum of Squares | 22211.4T |
Omega Non Current Assets Total History
About Omega Therapeutics Financial Statements
Omega Therapeutics stakeholders use historical fundamental indicators, such as Omega Therapeutics' Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Omega Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Omega Therapeutics' assets and liabilities are reflected in the revenues and expenses on Omega Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Omega Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 114.5 M | 120.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Omega Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Omega Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Omega Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Omega Therapeutics Stock:Check out the analysis of Omega Therapeutics Correlation against competitors. For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.32) | Revenue Per Share 0.114 | Quarterly Revenue Growth 1.812 | Return On Assets (0.25) | Return On Equity (1.29) |
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.